Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
294,683,714
-
Number of holders
-
197
-
Total 13F shares, excl. options
-
77,064,448
-
Shares change
-
+2,682,541
-
Total reported value, excl. options
-
$690,282,893
-
Value change
-
+$38,360,714
-
Put/Call ratio
-
76%
-
Number of buys
-
103
-
Number of sells
-
-56
-
Price
-
$8.96
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q2 2020
224 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q2 2020.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 197 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 77,064,448 shares
of 294,683,714 outstanding shares and own 26% of the company stock.
Largest 10 shareholders include BlackRock Inc. (10,345,516 shares), VANGUARD GROUP INC (8,471,895 shares), WASATCH ADVISORS INC (6,753,143 shares), STATE STREET CORP (6,488,918 shares), Bellevue Group AG (3,850,000 shares), CREDIT SUISSE AG/ (2,908,641 shares), DIMENSIONAL FUND ADVISORS LP (2,257,888 shares), TWO SIGMA INVESTMENTS, LP (2,125,535 shares), GEODE CAPITAL MANAGEMENT, LLC (1,772,502 shares), and GOLDMAN SACHS GROUP INC (1,619,211 shares).
This table shows the top 197 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.